Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer

被引：0
|
作者：
Yunokawa, Mayu [1 ]
机构：
[1] JFCR, Canc Inst Hosp, Gynecol Oncol & Med Oncol Dept, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz336.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS3 - 4
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [41] Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
    Fang-Fang Bi
    Da Li
    Qing Yang
    BMC Cancer, 13
  • [42] Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
    Kristeleit, Rebecca S.
    Oaknin, Ana
    Ray-Coquard, Isabelle
    Leary, Alexandra
    Balmana, Judith
    Drew, Yvette
    Oza, Amit M.
    Shapira-Frommer, Ronnie
    Domchek, Susan M.
    Cameron, Terri
    Maloney, Lara
    Goble, Sandra
    Lorusso, Domenica
    Ledermann, Jonathan A.
    McNeish, Iain A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (09) : 1396 - 1404
  • [43] Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer
    Garber, Haven R.
    Litton, Jennifer K.
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 247 - 255
  • [44] Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
    Bi, Fang-Fang
    Li, Da
    Yang, Qing
    BMC CANCER, 2013, 13
  • [45] Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
    Xu, Qin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    Safi, Adnan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 555 - 562
  • [47] Talazoparib for BRCA-mutated advanced breast cancer
    Gunjur, Ashray
    LANCET ONCOLOGY, 2018, 19 (10): : E511 - E511
  • [48] High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer
    Barnett, J. C.
    Kondoh, E.
    Whitaker, R.
    Murphy, S. K.
    Berchuck, A.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S107 - S107
  • [49] Lurbinectedin for BRCA-mutated advanced breast cancer
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (11): : E582 - E582
  • [50] SYSTEMATIC REVIEW OF POLY (ADP-RIBOSE) POLYMERASE INHIBITORS FOR TREATMENT OF OVARIAN CANCER
    Menges, B.
    Deitelzweig, C.
    Lin, J.
    Lingohr-Smith, M.
    Lin, G.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
12345